Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

EPOS/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023
W.J. Fokkens, A-S Viskens, V. Backer, et al.
Rhinology Journal (2023)
Open Access | Times Cited: 157

Showing 1-25 of 157 citing articles:

Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal Polyps
Brian J. Lipworth, Joseph K. Han, Martin Desrosiers, et al.
New England Journal of Medicine (2025)
Closed Access | Times Cited: 2
Two‐year results of tapered dupilumab for CRSwNP demonstrates enduring efficacy established in the first 6 months
Rik Johannes Leonardus van der Lans, Josje Janna Otten, Gwijde Flavius Jacobus Petrus Maria Adriaensen, et al.
Allergy (2023) Vol. 78, Iss. 10, pp. 2684-2697
Open Access | Times Cited: 39
Is generative pre-trained transformer artificial intelligence (Chat-GPT) a reliable tool for guidelines synthesis? A preliminary evaluation for biologic CRSwNP therapy
Antonino Maniaci, Alberto Maria Saibene, Christian Calvo‐Henríquez, et al.
European Archives of Oto-Rhino-Laryngology (2024) Vol. 281, Iss. 4, pp. 2167-2173
Closed Access | Times Cited: 11
Long-Term Perspectives on Chronic Rhinosinusitis with Nasal Polyps: Evaluating Recurrence Rates after Functional Endoscopic Sinus Surgery in the Biologics Era—A 5-Year Follow-Up Study
Carlo Cavaliere, Simonetta Masieri, Elona Begvarfaj, et al.
Journal of Personalized Medicine (2024) Vol. 14, Iss. 3, pp. 297-297
Open Access | Times Cited: 10
Correlation between inflammatory biomarkers and disease control in chronic rhinosinusitis with nasal polyps
Eugenio De Corso, Silvia Baroni, Stefano Settimi, et al.
International Forum of Allergy & Rhinology (2024) Vol. 14, Iss. 7, pp. 1195-1205
Open Access | Times Cited: 9
Efficacy and safety of dupilumab in the treatment of CRSwNP in the real-life setting: a review of the literature
Marella Reale, Giuseppe Licci, Pietro Orlando, et al.
European Archives of Oto-Rhino-Laryngology (2024) Vol. 281, Iss. 10, pp. 5023-5031
Closed Access | Times Cited: 9
Comparative real‐world outcomes of dupilumab versus endoscopic sinus surgery in the treatment of severe CRSwNP patients
Eugenio De Corso, Davide Paolo Porru, Marco Corbò, et al.
Clinical Otolaryngology (2024) Vol. 49, Iss. 4, pp. 481-489
Closed Access | Times Cited: 8
The use of biologics in patients suffering from chronic rhinosinusitis with nasal polyps – a 4-year real life observation
H. Frankenberger, Robert Wiebringhaus, Benedikt Paul, et al.
European Archives of Oto-Rhino-Laryngology (2024) Vol. 281, Iss. 11, pp. 5773-5782
Open Access | Times Cited: 8
Baseline disease characteristics by surgery history among patients with chronic rhinosinusitis with nasal polyps (CRSwNP) in the global AROMA registry
Shigeharu Fujieda, Jayant M. Pinto, David W. Jang, et al.
American Journal of Otolaryngology (2025) Vol. 46, Iss. 2, pp. 104596-104596
Open Access | Times Cited: 1
Effect of Dupilumab in CRSwNP Sinonasal Outcomes from Real Life Studies: A Systematic Review with Meta-analysis
Miguel Rodriguez-Iglesias, Christian Calvo‐Henríquez, Daniel Martín-Jiménez, et al.
Current Allergy and Asthma Reports (2025) Vol. 25, Iss. 1
Open Access | Times Cited: 1
Advances in Biologic Therapies for Allergic Diseases: Current Trends, Emerging Agents, and Future Perspectives
Ewa Alska, Dariusz Łaszczych, Katarzyna Napiórkowska-Baran, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 4, pp. 1079-1079
Open Access | Times Cited: 1
Clinical Evidence of the Use of Mepolizumab in the Treatment of Chronic Rhinosinusitis with Nasal Polyps: A Prospective Observational Study
Antonio Moffa, Francesco Iafrati, Lucrezia Giorgi, et al.
Healthcare (2025) Vol. 13, Iss. 4, pp. 419-419
Open Access | Times Cited: 1
Efficacy and Safety of Biologics for Chronic Rhinosinusitis With Nasal Polyps: A Meta‐Analysis of Real‐World Evidence
Shiru Cai, Shenglong Xu, Yan Zhao, et al.
Allergy (2025)
Open Access | Times Cited: 1
Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials
Philippe Gevaert, Martin Desrosiers, Marjolein Cornet, et al.
The Lancet (2025)
Closed Access | Times Cited: 1
Chinese Position Paper on Biologic Therapy for Chronic Rhinosinusitis With Nasal Polyps
Mu Xian, Bing Yan, Xicheng Song, et al.
Allergy (2025)
Open Access | Times Cited: 1
EUFOREA/EPOS2020 statement on the clinical considerations for chronic rhinosinusitis with nasal polyps care
Peter W. Hellings, Isam Alobid, Wilma Terezinha Anselmo‐Lima, et al.
Allergy (2023) Vol. 79, Iss. 5, pp. 1123-1133
Open Access | Times Cited: 21
Biologics for Chronic Rhinosinusitis—A Modern Option for Therapy
Romică Cergan, Ovidiu Berghi, Mihai Dumitru, et al.
Life (2023) Vol. 13, Iss. 11, pp. 2165-2165
Open Access | Times Cited: 19
Expert consensus on the use of systemic glucocorticoids for managing eosinophil-related diseases
Victoria del Pozo, Irina Bobolea, Manuel J. Rial, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access | Times Cited: 6
Long-Term Clinical Outcomes in Patients with Chronic Rhinosinusitis with Nasal Polyps Associated with Expanded Types of Endoscopic Sinus Surgery
Daniel-Iván Martín-Jiménez, Ramón Moreno‐Luna, M. Amparo Callejón, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 3, pp. 866-866
Open Access | Times Cited: 6
Real‐world data show sustained therapeutic effects of dupilumab in chronic rhinosinusitis with nasal polyps (CRSwNP) over 3 years
Patrick Huber, Ulrike Förster‐Ruhrmann, Heidi Olze, et al.
Allergy (2024) Vol. 79, Iss. 11, pp. 3108-3117
Open Access | Times Cited: 6
Influence of Prior Endoscopic Sinus Surgery Extent on Dupilumab Effectiveness in CRSwNP Patients
Matteo Alicandri‐Ciufelli, Daniele Marchioni, Carlotta Pipolo, et al.
The Laryngoscope (2023) Vol. 134, Iss. 4, pp. 1556-1563
Open Access | Times Cited: 15
Biologikatherapie bei schwer erkrankten Patienten mit „NSAID-exacerbated respiratory disease“ und stattgehabter ASS‑Desaktivierung
Anna-Rebekka Staufenberg, H. Frankenberger, Ulrike Förster‐Ruhrmann, et al.
HNO (2024) Vol. 72, Iss. 7, pp. 473-483
Open Access | Times Cited: 5
Efficacy of dupilumab in real-life settings: a STROBE study
A. Gal, R. Gravier-Dumonceau, M. Pénicaud, et al.
European Archives of Oto-Rhino-Laryngology (2024) Vol. 281, Iss. 9, pp. 4781-4788
Closed Access | Times Cited: 5
Omalizumab Treatment in Uncontrolled Asthma and CRSwNP Patients, with Previous Endoscopic Sinus Surgery, to Improve Quality of Life and Endoscopic Outcomes: a Two-Year Real-Life Study
Juan M. Solano, M. Amparo Callejón, Daniel Martín-Jiménez, et al.
Current Allergy and Asthma Reports (2023) Vol. 23, Iss. 10, pp. 555-566
Closed Access | Times Cited: 12
Biologics in severe uncontrolled chronic rhinosinusitis with nasal polyps: A bicentric experience.
Gianluca Bellocchi, Antonella Loperfido, Francesco Maria Passàli, et al.
PubMed (2023) Vol. 94, Iss. 5, pp. e2023227-e2023227
Closed Access | Times Cited: 11
Page 1 - Next Page

Scroll to top